Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study
et al., BMC Infectious Diseases, doi:10.1186/s12879-021-05773-w (date from earlier preprint)
, Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center.., BMC Infectious Diseases, doi:10.1186/s12879-021-05773-w (date from earlier preprint)
Retrospective 1,274 outpatients, 47% reduction in hospitalization with HCQ with propensity matching, HCQ OR 0.53 [0.29-0.95]. Sensitivity analyses revealed similar associations.Adverse events were not increased (2% QTc prolongation events, 0% arrhythmias).
|
risk of death, 54.5% lower, RR 0.45, p = 0.43, treatment 2 of 97 (2.1%), control 44 of 970 (4.5%), NNT 40.
|
|
risk of ICU admission, 28.6% lower, RR 0.71, p = 0.79, treatment 3 of 97 (3.1%), control 42 of 970 (4.3%), NNT 81.
|
|
risk of hospitalization, 37.3% lower, RR 0.63, p = 0.04, treatment 21 of 97 (21.6%), control 305 of 970 (31.4%), NNT 10, adjusted per study, odds ratio converted to relative risk.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Ip et al., 25 Aug 2020, retrospective, database analysis, USA, peer-reviewed, 25 authors, dosage not specified.
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.